Albert A. Holman III serves as Executive at BridgeBio Oncology Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Albert A. Holman III has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Aug 11, 2025 involved exercising options for 30,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | BBOT | $0 | Option Exercise | 30,000 | $N/A | Discretionary |
Albert A. Holman III currently holds 30,000 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Albert A. Holman III has been a net neutral trader of BBOT stock. They have purchased $0 and sold $0 worth of shares.
Albert A. Holman III's most recent insider trade was on Aug 11, 2025, when they sold 30,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted